Overview of Sales, Earnings and Financial Position
Bayer Links
News
 |
Nexavar® extends overall survival in patients with liver cancer Leverkusen. The cancer medicine Nexavar®, jointly developed by Bayer HealthCare and Onyx Pharmaceuticals, is also showing promising study results in liver cancer. The placebo-controlled phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer, met its primary endpoint resulting in superior overall survival. This means that overall survival was significantly extended in patients receiving Nexavar®. » more |
| Rachid El Kasmi, who works for Bayer HealthCare in Wuppertal, observes the isolation of sorafenib, the active ingredient in the new cancer medicine Nexavar®. |
| BayArena to be enlarged Leverkusen. The BayArena, the stadium that is home to the Bundesliga soccer team Bayer 04 Leverkusen, is to be modernized, enlarged and its capacity increased to accommodate over 30,000 spectators. Construction work costing some €56 million is scheduled to commence at the end of this year and be completed before the start of the 2009/2010 season. » more |
 |
| The future BayArena will be covered by a circular, tent-like roof integrating the company’s logo. Its 200 meters diameter will make it the world’s biggest Bayer Cross. |
 |
Bayer CropScience targets growth in China Beijing. Bayer CropScience is aiming for growth in China. The company plans to increase annual sales in the People’s Republic from the current level of €65 million (2006) to over €100 million in the medium term. In pursuit of this goal, Bayer CropScience will continue to systematically step up its commitment in China, one of the world’s fastest-growing markets for crop protection products. » more |
| In China, Bayer CropScience intends to expand the production of crop protection products and its hybrid rice seed business. |
| New study data on treatment of multiple sclerosis with Betaferon®/Betaseron® Berlin. According to new data recently announced by Bayer Schering Pharma AG, Germany*, immediate initiation of Betaferon®/Betaseron ® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent over three years compared to delayed treatment. » more |
 |
| In patients with multiple sclerosis, the myelin coatings around the nerve cells are destroyed. |
Further News:
Collaboration to develop new tomato varieties*
The names "Bayer Schering Pharma" or "Schering" as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.
Bookmark this page
E-mail this page
Advanced Search
